viewJohnson & Johnson

Pharma sales turbocharge Johnson & Johnson’s first-quarter earnings beat

Results exceeded Wall Street expectations for earnings and revenue

A magnifying glass makes the Johnson & Johnson name pop out
Shares rise in pre-market on positive outlook, revenue beat

Johnson & Johnson (NYSE:JNJ) crested Wall Street's first-quarter earnings and revenue expectations on Tuesday, fueled by strong pharmaceutical growth.

The New Brunswick, New Jersey, company reported net income of US$4.37bn, or US$1.60 per share. Adjusted per-share earnings were US$2.06, a nickel better than expected, according to a poll by Zacks Investment Research.

READ: Johnson & Johnson, Imerys ordered to pay additional US$80mln in punitive damages in talc-cancer case

The world’s biggest maker of healthcare products, clocked revenue of US$20bn, topping analysts' projections for US$19.48bn.

Shares of Johnson & Johnson rose nearly 1% to US$133 in pre-market trade.

Johnson & Johnson expects full-year earnings in the range of US$8 to US$8.20 per share, with revenue in the range of US$81bn to US$81.8bn.

"We had a very strong quarter. We carried our momentum from 2017 into 2018, and our pharmaceutical business continued to have stellar results," Johnson & Johnson Chief Financial Officer Dominic Caruso told CNBC.

The firm’s pharma business, especially cancer drug sales in Imbruvica and Darzalex, posted US$9.84bn in revenue, a 15% year-over-year operational jump in the quarter.

Quick facts: Johnson & Johnson

Price: 149.5 USD

Market: NYSE
Market Cap: $393.46 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Bull, Bears & Brokers: Shaw and Partner’s Davide Bosio talks about market...

Shaw and Partners WA state manager Davide Bosio updates Proactive on how share prices plunged this week, with stock market jitters in light of the coronavirus scare. Bosio gives his advice on how investors can protect their portfolios and takes a look at solid investment options during times...

9 hours, 33 minutes ago

2 min read